Memory Lapses During Menopause: Drugs That Cause or Treat Them

What Is Actually Happening in Your Brain During Menopause

Memory lapses during menopause are not imaginary and they are not early Alzheimer's disease. Your brain is responding to one of the largest hormonal shifts of your life. Estrogen acts as a neuroprotective agent, influencing synaptic density, cerebral blood flow, glucose metabolism, and the synthesis of acetylcholine, the neurotransmitter most tightly linked to memory encoding.

When estrogen falls, those systems lose a key regulatory signal. The Study of Women's Health Across the Nation (SWAN), which followed over 3,000 midlife women, found that processing speed and verbal memory declined significantly during the menopausal transition and then stabilized in the post-menopause years. The same study showed that women who reported more vasomotor symptoms had worse cognitive test scores, suggesting hot flashes and night sweats compound the neurological picture.

Sleep disruption is often the overlooked amplifier. A single night of fragmented sleep measurably reduces hippocampal memory consolidation. When night sweats wake you five times a night for eighteen months, the accumulated sleep debt does serious work on your recall.

The Estrogen-Acetylcholine Connection

Estrogen stimulates choline acetyltransferase, the enzyme that makes acetylcholine. Animal and human post-mortem studies confirm that estrogen withdrawal reduces cholinergic activity in the basal forebrain, the region responsible for attention and working memory. This is exactly why anticholinergic drugs, which block acetylcholine, hit menopausal women particularly hard.

The Hippocampus and Estradiol

Estradiol receptors are dense in the hippocampus and prefrontal cortex. MRI studies show measurable reductions in hippocampal grey matter volume during perimenopause, which partially recover in post-menopause. This transient structural change correlates with subjective memory complaints in most cohort studies.

Mood, Anxiety, and Cognitive Load

Depression and anxiety independently impair memory. The SWAN study also documented a two-fold increase in depressive symptoms during perimenopause compared with pre-menopause. When your working memory is already taxed by hormonal change, the additional cognitive load of depression or anxiety makes normal forgetting feel alarming.

Drugs That Make Menopause Memory Lapses Worse

Several commonly prescribed medications reduce memory in any adult. They hit menopausal women harder because your cholinergic reserve is already lower. Ask your prescriber to review your full medication list with this lens.

Anticholinergic Medications

These are the highest-risk category. The Anticholinergic Cognitive Burden (ACB) scale rates drugs by their acetylcholine-blocking potency. A JAMA Internal Medicine analysis found that cumulative anticholinergic drug use was associated with a significantly increased risk of dementia, with an odds ratio of 1.54 for the highest exposure group. Common anticholinergics prescribed to women include:

• Overactive bladder drugs: oxybutynin, tolterodine, solifenacin (oxybutynin is among the worst offenders on the ACB scale)
• Older antihistamines: diphenhydramine (Benadryl), hydroxyzine
• Tricyclic antidepressants: amitriptyline, nortriptyline
• Antiemetics: promethazine
• Bladder antispasmodics: dicyclomine

Importantly, mirabegron (Myrbetriq), a beta-3 agonist used for overactive bladder, is not anticholinergic and is a reasonable switch for menopausal women managing both bladder symptoms and cognitive concerns.

Benzodiazepines and Z-Drugs

Diazepam, lorazepam, alprazolam, zolpidem, and eszopiclone all depress hippocampal activity acutely and are associated with anterograde amnesia. A prospective study in the BMJ found that benzodiazepine use was associated with a 51% increased risk of Alzheimer's disease, though causality remains debated. Many women are prescribed these for anxiety or insomnia during perimenopause, two symptoms that are themselves best treated by addressing the hormonal root cause where possible.

Beta-Blockers

Propranolol and atenolol cross the blood-brain barrier and are linked to fatigue, low mood, and short-term memory difficulty. Metoprolol succinate and nebivolol have fewer central nervous system effects and may be preferable if a beta-blocker is clinically indicated.

Opioid Analgesics

Chronic opioid use reduces dopamine and impairs attention, working memory, and information processing speed. Women metabolize opioids differently from men due to differences in cytochrome P450 activity and body composition, which affects both efficacy and side-effect burden.

Statins (Lower Evidence, But Worth Knowing)

The relationship between statins and memory is contested. The FDA added a class labeling change in 2012 noting reports of memory impairment, but large observational studies and meta-analyses have not confirmed a causal link, and some data actually suggest statins are neuroprotective. Do not stop a statin for cognitive concerns without discussing the cardiovascular trade-off with your clinician.

Gabapentin and Pregabalin

Both drugs are used off-label for vasomotor symptoms in women who cannot take estrogen. They cause dose-dependent sedation, word-finding difficulty, and short-term memory impairment, especially at doses above 900 mg/day for gabapentin.

Hormone Therapy and Cognition: What the Evidence Actually Shows

Hormone therapy for menopause cognition is one of the most debated areas in women's health. The evidence is not as simple as "HRT fixes brain fog," but it is more encouraging than many women have been told.

The Timing Hypothesis

The Women's Health Initiative Memory Study (WHIMS) found that conjugated equine estrogen plus medroxyprogesterone acetate increased dementia risk in women aged 65-79. That result scared a generation of women and prescribers away from HRT. But those women were older, post-menopausal, and many had pre-existing cardiovascular risk. They were not representative of the perimenopausal women most troubled by brain fog.

The "timing hypothesis," now supported by multiple observational datasets and the KEEPS (Kronos Early Estrogen Prevention Study) trial, holds that estrogen initiated close to menopause onset, not a decade later, may support rather than harm cognitive function. The KEEPS trial found no cognitive harm and a trend toward improved verbal learning with oral conjugated estrogen or transdermal estradiol over four years in recently menopausal women.

Transdermal vs. Oral Estrogen

Transdermal estradiol avoids first-pass liver metabolism. This matters for cognitive outcomes because oral estrogen generates significant amounts of estrone sulfate, which may not have the same neuroprotective receptor affinity as 17-beta estradiol. Most European menopause specialists and The Menopause Society currently favour transdermal estradiol where HRT is appropriate.

Progesterone vs. Progestins

Micronized progesterone (Prometrium, Utrogestan) has a different receptor profile from synthetic progestins like medroxyprogesterone acetate. Laboratory data suggest micronized progesterone may be neuroprotective, while medroxyprogesterone acetate may partially blunt estrogen's cognitive benefits. The ELITE trial used micronized progesterone and showed cognitive stability. This distinction matters when you are choosing a progestogen with your prescriber.

What HRT Will Not Do

HRT is not an Alzheimer's prevention strategy. The Menopause Society's 2022 position statement on menopause and cognition explicitly states that evidence is insufficient to recommend hormone therapy solely for dementia prevention. For most women, initiating HRT in perimenopause for vasomotor and quality-of-life reasons may secondarily improve brain fog, primarily by improving sleep and reducing hot flashes that disrupt cognition.

Non-Hormonal Treatments for Menopause Brain Fog

Not every woman can or wants to take hormone therapy. Several evidence-based and evidence-adjacent strategies exist.

SSRIs and SNRIs

Escitalopram and venlafaxine reduce hot flashes by 40-60% in randomized trials, which may secondarily improve sleep and cognition. The MsFLASH trial found that escitalopram 10-20 mg reduced vasomotor symptom frequency by 47%, often within four weeks. They do not directly improve memory, but removing the hot-flash-sleep disruption cycle can noticeably clear brain fog.

Fezolinetant

Fezolinetant (Veozah) is a non-hormonal neurokinin 3 receptor antagonist approved by the FDA in May 2023 for moderate-to-severe vasomotor symptoms. By targeting the KNDy neurons that trigger hot flashes centrally, it reduces night sweats without estrogen. Improved sleep is the likely pathway to any cognitive benefit, though direct cognitive outcome data are not yet available.

Sleep-Targeted Interventions

Cognitive behavioral therapy for insomnia (CBT-I) is the AAFP and ACOG-recommended first-line treatment for chronic insomnia and outperforms pharmacotherapy for long-term outcomes. For menopausal women, CBT-I combined with sleep hygiene and vasomotor symptom control is more durable than a benzodiazepine prescription, which worsens the underlying problem.

Exercise and Cognitive Reserve

Aerobic exercise increases brain-derived neurotrophic factor (BDNF) and hippocampal volume. A 2022 Cochrane review of exercise interventions in menopausal women found moderate-quality evidence for improvement in cognitive function and quality of life. Even 150 minutes per week of moderate-intensity aerobic activity is a meaningful prescription.

Cognitive Training

Structured cognitive training (memory exercises, dual-task training) does not prevent dementia but does improve performance on trained tasks. It is most useful as a confidence-building tool during a period when subjective memory complaints often exceed objective deficits.

Pregnancy, Lactation, and Contraception: What Women Need to Know

This section applies to women in perimenopause who retain fertility and may still conceive, and to women using drugs for cognitive symptoms who need clarity on reproductive safety.

Can You Still Get Pregnant in Perimenopause?

Yes. Ovulation is irregular but not absent during perimenopause. ACOG confirms that contraception is recommended until 12 consecutive months without a period for women over 50, making unintended pregnancy a real risk even when cycles are erratic.

Drugs Reviewed in This Article: Pregnancy and Lactation Safety

Anticholinergic drugs: Most carry limited human pregnancy data. Oxybutynin is FDA Pregnancy Category B, but bladder urgency in pregnancy is best managed with pelvic floor therapy. In lactation, anticholinergics may suppress milk supply and should be used cautiously.

Benzodiazepines: Classified as FDA Pregnancy Category D. Neonatal withdrawal syndrome and cleft palate risk (debated but present in some cohort data) mean these should be avoided in pregnancy. In lactation, lorazepam and diazepam transfer into breast milk and cause infant sedation. A single dose may be acceptable; chronic use is not.

SSRIs (escitalopram, venlafaxine): ACOG's 2023 guidance on perinatal depression states that untreated depression carries significant maternal and fetal risk, and most SSRIs are reasonable to continue in pregnancy after individualized discussion. Neonatal adaptation syndrome is possible. In lactation, sertraline and paroxetine have the most reassuring infant serum level data, though escitalopram is also widely used.

Fezolinetant (Veozah): Contraindicated in pregnancy. No lactation data exist. Women in perimenopause using fezolinetant should use reliable contraception.

Hormone therapy (systemic estrogen/progesterone): Contraindicated in pregnancy. If a perimenopausal woman conceives while on HRT, it should be stopped and obstetric care initiated. Estrogen transfers into breast milk and is not recommended during lactation.

Gabapentin: FDA Pregnancy Category C. The North American AED Pregnancy Registry found an increased rate of preterm birth with gabapentin. It transfers into breast milk with infant levels reaching 36-80% of maternal serum concentration, which is not considered safe for nursing newborns without specialist guidance.

Who This Is Right For and Who Should Think Carefully

The following framework guides which women are likely to benefit most from specific interventions and which women need a different approach. This is original clinical stratification based on life-stage and drug-safety data synthesized from the sources cited above.

Women Most Likely to Benefit From HRT for Brain Fog

• Age 45-60 in natural perimenopause or early surgical menopause
• Bothersome vasomotor symptoms driving sleep disruption
• No personal history of estrogen receptor-positive breast cancer, DVT, PE, or active liver disease
• Baseline cardiovascular risk is low (use the ASCVD calculator)

Women Who Should Not Use HRT for This Indication

• History of hormone-sensitive breast cancer (ACOG and The Menopause Society both caution against systemic HRT in this group without oncology input)
• Active or recent DVT or pulmonary embolism
• Unexplained vaginal bleeding
• Women currently pregnant or trying to conceive

Women Whose Brain Fog Is Not Primarily Hormonal

If your memory lapses began well before perimenopause, if they are getting rapidly worse, if they include language loss, spatial disorientation, or personality change, or if they persist two or more years after your last period without improvement, a formal neuropsychological evaluation is warranted. The Alzheimer's Association recommends evaluation for any memory symptoms that interfere with daily life, even in midlife, and your primary care provider or a neurologist can order standardized assessments such as the MoCA (Montreal Cognitive Assessment).

Life-Stage Summary Table

| Life Stage | Primary Driver of Memory Lapses | First-Line Approach | |---|---|---| | Perimenopause (35-51) | Estrogen fluctuation, sleep disruption, depression | Treat vasomotor symptoms, CBT-I, review drug list | | Early post-menopause (<5 years from FMP) | Estrogen deficiency stabilizing | HRT if eligible, aerobic exercise, cognitive training | | Late post-menopause (>10 years from FMP) | Age-related neurodegeneration, comorbidities | Full neuropsychological workup, cardiovascular risk reduction | | Surgical menopause | Abrupt estrogen loss (often more severe) | Prompt HRT unless contraindicated, specialist referral | | Perimenopause + PCOS | Insulin resistance may amplify cognitive risk | Metabolic management plus hormonal support |

Diagnosing Menopause-Related Memory Lapses

No single blood test diagnoses menopause brain fog. Diagnosis is clinical, built from your history, symptom timing, and exclusion of other causes.

What Your Clinician Will Rule Out First

A thyroid panel (TSH and free T4) is essential. Hypothyroidism affects 8-10% of women over 40 and produces memory, concentration, and word-finding problems that perfectly mimic menopause brain fog. Vitamin B12 deficiency, folate deficiency, sleep apnea, uncontrolled diabetes, and anaemia are also on the differential and are all treatable.

Objective Cognitive Testing

Standard office tools like the MoCA take seven minutes and detect mild cognitive impairment with reasonable sensitivity. A MoCA score of 26 or below suggests mild cognitive impairment and warrants further evaluation. Most menopausal women with subjective memory complaints score in the normal range, which itself is reassuring and clinically useful data.

FSH and Estradiol Levels

An FSH above 40 mIU/mL on two measurements 6 weeks apart, in a woman over 45 without a period for 12 months, confirms menopause. Estradiol below 30 pg/mL is consistent with post-menopausal levels. These numbers support the hormonal diagnosis but do not quantify cognitive impact. Hormone levels correlate poorly with symptom severity across individuals.

When to Escalate: Red Flags That Need More Than a Menopause Conversation

Memory lapses that cause you to miss appointments you keep a calendar for, forget conversations that happened an hour ago, get lost driving familiar routes, or lose words in mid-sentence (not just tip-of-tongue, but full stops) need a neurological evaluation. These are not typical menopause symptoms.

The Lancet 2024 Commission on Dementia Prevention identified 14 modifiable risk factors, several of which are directly relevant to menopausal women: hypertension, obesity, physical inactivity, depression, and untreated hearing loss. Addressing these is not separate from managing brain fog, it is the same conversation.

Your clinician should refer you to a neurologist or geriatrician if:

• Symptoms are rapidly progressive over fewer than 6 months
• There is a first-degree family history of early-onset dementia
• Objective cognitive testing shows impairment on two or more domains
• You are more than five years past your final menstrual period and symptoms are worsening rather than stabilizing